DNA and DNA synthesis machinery

DNA and the machinery responsible for its synthesis constitute a fundamental therapeutic target in medicine, particularly in oncology and infectious diseases [1, 2]. This target encompasses the DNA molecule itself and a complex assembly of enzymes, such as DNA polymerases, helicases, and topoisomerases, that coordinate to replicate the genome [2, 4]. Drugs targeting this system work by directly damaging DNA (e.g., alkylating agents), mimicking nucleotides to stall synthesis (e.g., antimetabolites), or inhibiting the enzymes that manage DNA topology and repair [3, 5]. While highly effective at killing rapidly dividing cells like cancer cells or pathogens, these agents often lack specificity, leading to significant side effects such as bone marrow suppression and organ toxicity [11]. Modern precision medicine aims to target specific components of the DNA synthesis and repair pathways, such as PARP or ATR, to exploit specific genetic vulnerabilities in tumors through mechanisms like synthetic lethality [8, 14, 16].

Other names

DNA replication machineryReplisomeDNA synthesis apparatusDeoxyribonucleic acidDNA replication complex

Drugs targeting this machinery operate through several distinct mechanisms: DNA alkylation and cross-linking (e.g., platinum agents), which physically obstruct replication; antimetabolites (e.g., 5-FU), which deplete nucleotide pools or act as chain terminators; topoisomerase inhibition (e.g., anthracyclines), which prevents DNA unwinding; and DNA repair inhibition (e.g., PARP inhibitors), which induces synthetic lethality in cells with existing repair defects [1, 3, 4, 5, 8].